Objective: The relapse rate of Graves' hyperthyroidism after finishing an antithyroid cicle is high. The objective of this work was to prospectively investigate the relapse rate of Graves' hyperthyroidism (GH) in patients with maintenance of a low dose of antithyroid drug (ATD) therapy.

Patients And Method: From March 1997, all patients with GH consecutively attending the same center who remained euthyroid with low doses of synthetic ATD (carbimazole or methimazole: 2.5-5mg/day) on 2 consecutive follow-up visits (at 10-12 months) were included in this study. Instead of withdrawing ATD, the aim was to continue with this low dose for a 5-year period (group M: 53 patients). From March 1997, data were also collected from patients with GH who were consecutively followed-up and who, meeting the criteria for inclusion in group M, had stopped receiving ATD before the start of the study (March 1997) (group R: 31 patients).

Main Outcome: GH relapse was observed in 12/53 patients in group M (22.64%) and in 24/31 patients in group R (77.42%) (p<0.000).

Conclusions: The GH relapse rate was significantly lower with long-term maintenance of a low dose of ATD than with therapy withdrawal.

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1575-0922(08)70648-XDOI Listing

Publication Analysis

Top Keywords

graves' hyperthyroidism
12
march 1997
12
relapse rate
8
rate graves'
8
low dose
8
patients consecutively
8
patients group
8
patients
7
group
5
long-term maintenance
4

Similar Publications

Autoimmune Thyroid Disease in Patients with Down Syndrome-Review.

Int J Mol Sci

December 2024

Department of Endocrinology, Metabolism and Internal Medicine, Poznan University of Medical Sciences, 60-355 Poznan, Poland.

Down syndrome develops due to the presence of supernumerary chromosome 21. This diagnosis is made in approximately 1:800 live births. The tendency to develop autoimmune disorders like idiopathic arthritis, celiac disease, diabetes mellitus type 1, vitiligo and autoimmune thyroid disease is strongly expressed in patients with Down syndrome.

View Article and Find Full Text PDF

Treatment of Hyperthyroidism in Graves' Disease Complicated by Thyroid Eye Disease.

J Clin Endocrinol Metab

January 2025

Department of Ophthalmology and Visual Sciences and Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI 48105  USA.

Thyroid eye disease (TED) is the most consequential extrathyroidal manifestation or complication of Graves' disease (GD). Treatment of hyperthyroidism in GD complicated by TED is challenging. Antithyroid drugs (ATDs) and thyroidectomy do not change the natural course of TED, while radioactive iodine (RAI) is associated with a small but well-documented risk of TED de novo occurrence or its progression/worsening.

View Article and Find Full Text PDF

Purpose: To study the feasibility and value of assessing patients with Graves' orbitopathy (GO) in 99mTc-diethylenetriamine pentaacetic acid (DTPA) orbital single photon emission computed tomography/computed tomography (SPECT/CT) with extraocular muscle maximum standardized uptake value (SUVmax).

Methods: A total of 235 patients underwent 99mTc-DTPA orbital SPECT/CT, including 176 patients with GO and 59 patients with Graves' disease (GD) as controls. The SUVmax of extraocular muscles, including right medial rectus muscle (RMR), right lateral rectus muscle (RLR), left medial rectus muscle (LMR), left lateral rectus muscle (LLR), was compared between groups, correlation analyses with clinical activity scores (CAS) and serological indices was performed, and the diagnostic efficacy was evaluated using receiver operating characteristic curves.

View Article and Find Full Text PDF

Thyroid eye disease (TED) is a common extrathyroidal manifestation of hyperthyroidism, typically associated with Graves' disease (GD). This condition can cause severe functional limitations as well as significant aesthetic concerns. Treatment for TED patients aims to restore functionality and address aesthetic concerns.

View Article and Find Full Text PDF

Graves' disease diagnosed nearly six months after microwave ablation of benign thyroid nodules: a case report.

BMC Endocr Disord

January 2025

Department of Endocrine and Metabolic Diseases, The First People's Hospital of Changzhou, The Third Affiliated Hospital of Soochow University, No. 185, Juqian Street, Changzhou, 213000, Jiangsu, China.

Background: Microwave ablation is a new, minimally invasive technique for the treatment of thyroid nodules. Hyperthyroidism due to destructive thyroiditis is a known risk of microwave ablation, though it occurs in only a minority of cases. We report a rare case of a patient diagnosed with Graves' disease nearly six months after undergoing microwave ablation of a thyroid nodule.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!